title: [Genomic signature of breast cancer: The quest for the Holy Grail].
abstract: The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the limits to be clarified before using commercial molecular signatures.
authors.affiliation: Département d'oncologie médicale, Institut Bergonié, Bordeaux, France. Electronic address: M.Debled@bordeaux.unicancer.fr.
authors.forename: Marc
authors.initials: M
authors.lastname: Debled
authors.affiliation: Département d'oncologie médicale, Institut Bergonié, Bordeaux, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Chakiba
authors.affiliation: Département de biopathologie, Institut Bergonié, Bordeaux, France.
authors.forename: Gaétan
authors.initials: G
authors.lastname: MacGrogan
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003132:Commerce; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D006801:Humans; D011237:Predictive Value of Tests; D011379:Prognosis; D015203:Reproducibility of Results
keywords: Breast cancer; Cancer du sein; Molecular signatures; Prediction; Prognosis; Pronostic; Prédiction; Signature moléculaire